Red X iconGreen tick iconYellow tick icon

Contact Details

Phone
64 3 364 0530
Email
paul.chin@otago.ac.nz
Position
Senior Lecturer
Department
Department of Medicine (Christchurch)
Qualifications
MB ChB

Research

Paul Chin is a Clinical Pharmacologist. His research interests include pharmacokinetics and therapeutic drug monitoring.

Publications

Sundermann, M., Clendon, O., McNeill, R., Doogue, M., & Chin, P. K. L. (2024). Optimising interruptive clinical decision support alerts for antithrombotic duplicate prescribing in hospital. International Journal of Medical Informatics, 186, 104418. doi: 10.1016/j.ijmedinf.2024.105418 Journal - Research Article

Morahan, M.-C., Yorkston, D., Knight, J., Borrie, T., Hastie, B., & Chin, P. (2023). The Covid-19 pandemic perspective from a New Zealand medicines information service. Pharmacy Education, 23(6), (pp. 176-177). doi: 10.46542/pe.2023.236.158191 Conference Contribution - Published proceedings: Abstract

Pairman, L., Chin, P., McNeill, R., & Doogue, M. (2023). The effect of compulsory indications in electronic hospital prescriptions on prescriber behaviour. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. 435. Retrieved from https://www.asceptasm.com Conference Contribution - Published proceedings: Abstract

Barclay, M. L., Keating, P. E., Hock, B. D., Chin, P. K. L., & O'Donnell, J. L. (2023). Infliximab or adalimumab antidrug-antibody complex size has more clinical value than concentration. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. 235. Retrieved from https://www.asceptasm.com Conference Contribution - Published proceedings: Abstract

Barclay, M. L., Keating, P. E., Hock, B. D., Smith, S. M., Chin, P. K. L., & O'Donnell, J. L. (2023). Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating high potential for improved dosing. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. P513. Retrieved from https://www.asceptasm.com Conference Contribution - Published proceedings: Abstract

Back to top